NCT06754059View on ClinicalTrials.gov

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2027

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

Pyrotinib

In this study, after at least 4 cycles of taxoid chemotherapy combined with trastuzumab ± pertuzumab, the evaluation result reached SD, CR or PR, and capecitabine combined with pyrotinib + trastuzumab was given successively in the later period (capecitabine was used for 4-6 cycles

Trial Locations (1)

350000

RECRUITING

Fujian Union Medical College Hospital, Fuzhou

All Listed Sponsors
lead

zhangjie

OTHER

NCT06754059 - Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC | Biotech Hunter | Biotech Hunter